Clinical Trial of Favipiravir Treatment of Patients With COVID-19

Phase 3

Completed

• Conditions: SARS-CoV-2 Infection
• Interventions: Drug: Favipiravir

• Registration Number: NCT04600999
• Lead Sponsor: University of Pecs

Brief Summary

To verify that the efficacy of favipiravir exceeds that of the actual supportive care (symptomatic therapy) in SARS-CoV-2 infected patients (COVID-19 patients) with mild pneumonia, using the time required to improve clinical symptoms as the primary endpoint.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-10-07
• Study First Submitted: 2020-10-08
• Study First Submitted QC: 2020-10-22
• Study First Posted: 2020-10-23
• Primary Completion: 2020-12-28
• Study Completion: 2020-12-28
• Status Verified: 2022-10
• Last Update Submitted: 2022-10-30
• Last Update Posted: 2022-11-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

1. Age 18 to 74 years (at the time of informed consent)

2. Male or female

3. Patients who meet all of the following three criteria at the time of enrolment:

   1. SARS-CoV-2-positive patients as measured by rtPCR by nasopharyngeal sampling
   2. Moderate patients with radiological evidence of pneumonia in the lung at the time of enrolment (RTG, CT, or UH), clearly described by the radiologist following the imaging examination. (The diagnosis of the finding should clearly include the presence of pneumonia to any extent, localization, and extent)
   3. Body temperature 37,5°C or more
   4. Patient requires hospitalization during the treatment period (obligation to stay in the hospital for whole treatment period, 14 days)

4. For premenopausal females, patients who have been confirmed to be negative on a pregnancy test before administration of the study drug

5. Signed informed consent by the patient or by the legal representative -

Read More

Exclusion Criteria

1. Body temperature of 37.5 °C or higher for more than 10 days after the onset of elevated body temperature

2. Patients with SpO2 less than 95%

3. Patient requires supportive oxygen therapy

4. Patients who show increased procalcitonin levels before the start of the study drug administration and are suspected to have concurrent bacterial infection

5. Patients with proven concomitant systematic fungal infection prior to initiation of study drug.

6. Patients with concurrent congestive heart failure (NYHA III-IV)

7. Patients with severe hepatic impairment equivalent to Grade C on Child-Pugh classification

8. Patient with renal impairment requiring dialysis.

9. Patients with disturbed consciousness such as disturbed orientation.

10. Pregnant or possibly pregnant patients.

11. Female patients who are woman of childbearing potential and unable to consent to the use of dual contraception from the start of favipiravir administration to 30 days after the end of favipiravir administration. Dual contraception is a combination of two of the following: Barrier method of contraception: condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide; IUD; Hormone-based contraceptive; Tubal ligation

12. Male patients whose are unable to consent to the use of the barrier method of contraception (condom) from the start of favipiravir administration to 90 days after the end of favipiravir administration. Male patients who are planning to donate sperm from the start up until 90 days after the end of favipiravir administration.

13. Female patients who intend to breastfeed from the start of favipiravir administration until 14 days after discontinuation of favipiravir administration

14. Patients with herditary xanthinuria

15. Patients who have hyperuricemia (> 1 mg/dL) or xanthine urinary calculi

16. Patients with a history of gout or on treatment for gout or hyperuricemia

17. Patients receiving immunosuppressants

18. Patients who received interferon-alpha or drugs with reported antiviral activity against SARS-CoV-2 (hydroxychloroquine sulfate, chloroquine phosphate, lopinavir-ritonavir combination, ciclesonide, nafamostat mesylate, camostat mesylate, remdesivir, etc.) within 9 days after fever onset (37.5°C or more)

19. Patients in whom this episode of infection is a recurrence or a reinfection with the SARS-CoV-2 infection

20. Patients who have previously been treated with favipiravir (T-705a)

21. Other patients judged ineligible by the investigator, sub-investigator, or assigned physician.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group Avigan	Favipiravir	Favipiravir from Day1 + Supportive care (symptomatic therapy) a regimen of 3600 mg (1800 mg twice a day orally) loading dose on Day1 followed by 1600 mg maintenance dose (800 mg twice a day orally) on Day2 to Day14.

Primary Outcome Measures

Name	Time	Method
Time to improvement in body temperature	9 month
Time to improvement in SpO2	9 month
Time to improvement in chest imaging findings	9 month
Time to improvement in negative SARS-CoV-2	9 month

Secondary Outcome Measures

Name	Time	Method
(8) Percentage of patients requiring adjuvant oxygen therapy	9 month
(8) Adjuvant oxygen therapy average duration	9 month
(1) Changes in patient status on a 5-point scale	9 month	Name of the scale is: Patient Status Score. 1:A condition in which the patient can be discharged; 5:A condition requiring ECMO or invasive oxygen therapy and ICU management
(3) SARS-CoV-2 virus genome clearance rate	9 month
(9) Percentage of patients requiring mechanical ventilation therapy	9 month
(2) Changes in the level of SARS-CoV-2 viral genome	9 month
(4) Duration of pyrexia	9 month
(6) Changes in NEWS (National Early Warning Score)	9 month	Changes in NEWS (unabbreviated scale title: National Early Warning Score). Calculate the total value from the clinical symptoms and findings (consciousness) and vital signs (SpO2, body temperature, blood pressure, pulse rate, respiratory rate). 0 is normal
(7) Changes in chest imaging findings on Days 4,7,10,13,16,19,22,25,28.	Changes in chest imaging findings will be collected and checked on Days 4,7,10,13,16,19,22,25,28, the data will be analyzied at 9. month.
(5) Changes in clinical symptoms	9 month	Changes in clinical symptoms, including: Patient's condition; Coughing, Sore throat, Headache, Muscle or joint pain, Nasal congestion or Nasal discharge, Chills or sweating, Malaise or fatigue, Chest pain, dehydration, cyanosis, pleural effusion, Thoracic rales, Conscious state.
(9)Adjuvant oxygen therapy average durationduration	9 month

Trial Locations

Locations (5)

First Department of Internal Medicine, University of Szeged; 🇭🇺 Szeged, Hungary

National Korányi Institute for Pulmonology; 🇭🇺 Budapest, Hungary

Institute of Infectology, University of Debrecen; 🇭🇺 Debrecen, Hungary

1st Department of Medicine, University of Pécs; 🇭🇺 Pécs, Hungary

Department of Pulmonology Semmelweis University; 🇭🇺 Budapest, Hungary